QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform

Reuters

05-13

QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform

QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512358698) on May 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535078941"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535078941\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535078941?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535078941","market":"nz","top_or_hot":-1,"title":"QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512358698) on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-13 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512358698) on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125909593.SGD","symbol_name":"Natixis Thematics Meta R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDL3FPyQL:1","article_id":"2535078941","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535078941","pubTimestamp":1747080336,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4121":"生命科学工具和服务","QGEN":"快而精医药","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD"},"translate_title":"QIAGEN以7000万美元收购Genoox，通过人工智能平台增强临床基因组学产品组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform\n    \n\n        QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512358698) on May 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}